Page last updated: 2024-08-07 16:31:07
Cytochrome P450 2C19
A cytochrome P450 2C19 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P33261]
Synonyms
EC 1.14.14.1;
(R)-limonene 6-monooxygenase;
1.14.14.53;
(S)-limonene 6-monooxygenase;
1.14.14.51;
(S)-limonene 7-monooxygenase;
1.14.14.52;
CYPIIC17;
CYPIIC19;
Cytochrome P450-11A;
Cytochrome P450-254C;
Fenbend
Research
Bioassay Publications (207)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 1 (0.48) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 44 (21.26) | 29.6817 |
| 2010's | 131 (63.29) | 24.3611 |
| 2020's | 31 (14.98) | 2.80 |
Compounds (276)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| bupropion | Homo sapiens (human) | IC50 | 1.9983 | 1 | 0 |
| pleconaril | Homo sapiens (human) | IC50 | 30.0594 | 2 | 2 |
| tacrine | Homo sapiens (human) | IC50 | 0.1143 | 1 | 1 |
| acetazolamide | Homo sapiens (human) | Ki | 0.0739 | 5 | 6 |
| alosetron | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| benzbromarone | Homo sapiens (human) | Ki | 3.7000 | 1 | 1 |
| 5-methoxypsoralen | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| ci 994 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| ciprofloxacin | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| clotrimazole | Homo sapiens (human) | IC50 | 0.0160 | 1 | 0 |
| dichlorphenamide | Homo sapiens (human) | Ki | 0.0500 | 1 | 1 |
| econazole | Homo sapiens (human) | IC50 | 0.0400 | 1 | 0 |
| ethoxzolamide | Homo sapiens (human) | Ki | 0.0220 | 1 | 1 |
| fluorescite | Homo sapiens (human) | IC50 | 0.9074 | 1 | 0 |
| fluoxetine | Homo sapiens (human) | IC50 | 0.0525 | 2 | 2 |
| furafylline | Homo sapiens (human) | IC50 | 0.3000 | 1 | 1 |
| hexachlorophene | Homo sapiens (human) | IC50 | 1.2265 | 1 | 0 |
| miltefosine | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| phenelzine | Homo sapiens (human) | IC50 | 0.8000 | 1 | 0 |
| idebenone | Homo sapiens (human) | IC50 | 0.8000 | 1 | 0 |
| isoniazid | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| khellin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| kojic acid | Homo sapiens (human) | IC50 | 12.4446 | 1 | 2 |
| lansoprazole | Homo sapiens (human) | IC50 | 0.3367 | 1 | 0 |
| loratadine | Homo sapiens (human) | IC50 | 0.0160 | 1 | 0 |
| mephenytoin | Homo sapiens (human) | IC50 | 1.1850 | 2 | 2 |
| methazolamide | Homo sapiens (human) | Ki | 0.0034 | 1 | 1 |
| metyrapone | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| miconazole | Homo sapiens (human) | IC50 | 8.9790 | 4 | 3 |
| modafinil | Homo sapiens (human) | IC50 | 11.0000 | 3 | 3 |
| entinostat | Homo sapiens (human) | IC50 | 3.9300 | 1 | 1 |
| nimodipine | Homo sapiens (human) | IC50 | 4.0000 | 1 | 0 |
| nitrendipine | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| nomifensine | Homo sapiens (human) | IC50 | 0.0316 | 1 | 1 |
| nortriptyline | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| omeprazole | Homo sapiens (human) | IC50 | 2.3150 | 2 | 2 |
| oxybutynin | Homo sapiens (human) | IC50 | 0.6000 | 1 | 0 |
| papaverine | Homo sapiens (human) | IC50 | 0.7620 | 1 | 0 |
| pentamidine | Homo sapiens (human) | IC50 | 75.0000 | 3 | 3 |
| propranolol | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| riluzole | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| vorinostat | Homo sapiens (human) | IC50 | 0.0420 | 2 | 2 |
| sulconazole | Homo sapiens (human) | IC50 | 0.0160 | 1 | 0 |
| sulfaphenazole | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| thioridazine | Homo sapiens (human) | IC50 | 6.3778 | 1 | 0 |
| ticlopidine | Homo sapiens (human) | IC50 | 0.6678 | 1 | 0 |
| ticlopidine | Homo sapiens (human) | Ki | 45.1500 | 2 | 2 |
| tolnaftate | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| tropicamide | Homo sapiens (human) | IC50 | 1.0000 | 1 | 0 |
| norethindrone acetate | Homo sapiens (human) | IC50 | 0.8000 | 1 | 0 |
| spironolactone | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| rotenone | Homo sapiens (human) | IC50 | 3.6486 | 1 | 0 |
| phenylhydrazine | Homo sapiens (human) | IC50 | 5.0000 | 1 | 0 |
| maltol | Homo sapiens (human) | IC50 | 199.7630 | 1 | 2 |
| chlormadinone acetate | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| naphthazarin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| plumbagin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| podophyllotoxin | Homo sapiens (human) | IC50 | 5.0000 | 1 | 0 |
| medroxyprogesterone | Homo sapiens (human) | IC50 | 2.0000 | 1 | 0 |
| 2,2-dimethylbutyric acid | Homo sapiens (human) | IC50 | 10,000.0000 | 2 | 2 |
| alpha-naphthoflavone | Homo sapiens (human) | IC50 | 15.0000 | 4 | 4 |
| ethylestrenol | Homo sapiens (human) | IC50 | 1.2907 | 1 | 0 |
| 2-amino-6-methoxybenzothiazole | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| tranylcypromine | Homo sapiens (human) | IC50 | 8.3689 | 9 | 9 |
| stanozolol | Homo sapiens (human) | IC50 | 0.0480 | 1 | 0 |
| clemastine | Homo sapiens (human) | IC50 | 0.6000 | 1 | 0 |
| benzonidazole | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| nitrogenase stabilizing-protective protein, bacteria | Homo sapiens (human) | GI50 | 1.8000 | 1 | 4 |
| nitrogenase stabilizing-protective protein, bacteria | Homo sapiens (human) | IC50 | 1.0000 | 1 | 0 |
| finasteride | Homo sapiens (human) | IC50 | 1.0000 | 1 | 0 |
| clopidogrel | Homo sapiens (human) | Ki | 14.3000 | 1 | 1 |
| duloxetine | Homo sapiens (human) | IC50 | 4.1000 | 2 | 2 |
| proadifen hydrochloride | Homo sapiens (human) | IC50 | 19.0000 | 1 | 1 |
| isopimpinellin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| pyromeconic acid | Homo sapiens (human) | IC50 | 23.8094 | 1 | 2 |
| sertraline | Homo sapiens (human) | IC50 | 0.6550 | 2 | 1 |
| pirlindole | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| allomaltol | Homo sapiens (human) | IC50 | 16.4744 | 1 | 2 |
| voriconazole | Homo sapiens (human) | IC50 | 8.7000 | 1 | 1 |
| 6-paradol | Homo sapiens (human) | IC50 | 5.8000 | 1 | 1 |
| phellopterin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| sr141716 | Homo sapiens (human) | IC50 | 0.0069 | 1 | 1 |
| sch 28080 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| mosapride | Homo sapiens (human) | IC50 | 1.0000 | 1 | 0 |
| methylthio-adp | Homo sapiens (human) | IC50 | 0.0400 | 1 | 1 |
| desethylamodiaquine | Homo sapiens (human) | IC50 | 54.0000 | 2 | 2 |
| gefitinib | Homo sapiens (human) | IC50 | 0.1510 | 1 | 1 |
| chs 828 | Homo sapiens (human) | IC50 | 0.0010 | 1 | 1 |
| tariquidar | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| 5-hydroxy-3',4',6,7-tetramethoxyflavone | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| pumosetrag | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| anidulafungin | Homo sapiens (human) | IC50 | 17.5000 | 1 | 1 |
| 8-gingerol | Homo sapiens (human) | IC50 | 27.6000 | 2 | 2 |
| 10-gingerol | Homo sapiens (human) | IC50 | 13.6000 | 1 | 1 |
| sb 203580 | Homo sapiens (human) | IC50 | 0.8000 | 1 | 0 |
| erlotinib | Homo sapiens (human) | IC50 | 0.0870 | 1 | 1 |
| n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide | Homo sapiens (human) | Ki | 0.0034 | 1 | 1 |
| sr 142806 | Homo sapiens (human) | IC50 | 7.0000 | 1 | 1 |
| noscapine | Homo sapiens (human) | IC50 | 0.4003 | 1 | 0 |
| ritonavir | Homo sapiens (human) | IC50 | 12.7000 | 1 | 1 |
| linezolid | Homo sapiens (human) | Ki | 53.0000 | 1 | 1 |
| gingerol | Homo sapiens (human) | IC50 | 30.7000 | 1 | 1 |
| sb 221284 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| sb 228357 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| sb 243213 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| tibolone | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| dihydroergocristine monomesylate | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| trichostatin a | Homo sapiens (human) | IC50 | 0.0050 | 1 | 1 |
| resveratrol | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| abt 492 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| bay 57-1293 | Homo sapiens (human) | Ki | 0.2863 | 2 | 3 |
| bms-488043 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| cannabidiol | Homo sapiens (human) | Ki | 0.7900 | 1 | 1 |
| pongamol | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| epalrestat | Homo sapiens (human) | IC50 | 0.0850 | 1 | 1 |
| n-hydroxy-n'-(4-butyl-2-methylphenyl)formamidine | Homo sapiens (human) | IC50 | 0.2720 | 1 | 1 |
| maraviroc | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| telaprevir | Homo sapiens (human) | Ki | 0.0820 | 1 | 1 |
| orlistat | Homo sapiens (human) | IC50 | 0.4200 | 1 | 1 |
| vx-745 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| dasatinib | Homo sapiens (human) | IC50 | 50.0000 | 1 | 0 |
| blister | Homo sapiens (human) | IC50 | 150.0000 | 1 | 1 |
| sb 242084 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| calcitriol | Homo sapiens (human) | Ki | 0.0001 | 1 | 1 |
| amphotericin b | Homo sapiens (human) | IC50 | 96.0000 | 1 | 1 |
| cyclosporine | Homo sapiens (human) | IC50 | 7.0000 | 1 | 1 |
| sirolimus | Homo sapiens (human) | IC50 | 4.0000 | 1 | 0 |
| topiramate | Homo sapiens (human) | Ki | 0.0300 | 1 | 1 |
| geldanamycin | Homo sapiens (human) | IC50 | 0.0740 | 1 | 1 |
| istradefylline | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| lacidipine | Homo sapiens (human) | IC50 | 2.0000 | 1 | 0 |
| sb 223412 | Homo sapiens (human) | IC50 | 9.0000 | 1 | 1 |
| (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone | Homo sapiens (human) | Ki | 0.0020 | 1 | 1 |
| palbociclib | Homo sapiens (human) | Ki | 5.0000 | 1 | 1 |
| guttiferone e | Homo sapiens (human) | IC50 | 0.5000 | 1 | 1 |
| oxiconazole | Homo sapiens (human) | IC50 | 0.0400 | 1 | 0 |
| bedaquiline | Homo sapiens (human) | IC50 | 5.8000 | 2 | 2 |
| bms 806 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| mdl 73811 | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| rilpivirine | Homo sapiens (human) | IC50 | 0.3363 | 4 | 4 |
| scy-635 | Homo sapiens (human) | IC50 | 12.4000 | 1 | 1 |
| opc-67683 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| ispinesib | Homo sapiens (human) | IC50 | 24.3000 | 1 | 1 |
| fk 866 | Homo sapiens (human) | IC50 | 0.0010 | 1 | 1 |
| (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone | Homo sapiens (human) | IC50 | 0.0110 | 1 | 2 |
| bis(7)-tacrine | Homo sapiens (human) | IC50 | 0.0053 | 1 | 1 |
| nifursol | Homo sapiens (human) | IC50 | 5.0000 | 1 | 0 |
| dov 216303 | Homo sapiens (human) | IC50 | 1.6000 | 1 | 1 |
| orteronel | Homo sapiens (human) | IC50 | 14.0000 | 1 | 1 |
| CB-13 | Homo sapiens (human) | Ki | 0.0190 | 1 | 1 |
| n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide | Homo sapiens (human) | IC50 | 7.1100 | 1 | 1 |
| gw 803430 | Homo sapiens (human) | IC50 | 9.3000 | 1 | 1 |
| biln 2061 | Homo sapiens (human) | Ki | 0.0240 | 1 | 1 |
| mocetinostat | Homo sapiens (human) | IC50 | 0.1020 | 1 | 1 |
| ic 87114 | Homo sapiens (human) | IC50 | 0.1300 | 1 | 1 |
| dirlotapide | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| tofacitinib | Homo sapiens (human) | IC50 | 0.0016 | 1 | 1 |
| linaprazan | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| chf 5074 | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| pimavanserin | Homo sapiens (human) | IC50 | 49.8000 | 1 | 1 |
| 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7h-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| way 181187 | Homo sapiens (human) | IC50 | 163.2857 | 2 | 7 |
| bibw 2992 | Homo sapiens (human) | IC50 | 0.0370 | 1 | 1 |
| 6-(3-hydroxyphenyl)-2-naphthol | Homo sapiens (human) | IC50 | 7.5400 | 1 | 1 |
| gw 842166x | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| gsk 369796 | Homo sapiens (human) | IC50 | 24.0000 | 1 | 1 |
| ps 540446 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| sb-435495 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| bms 599626 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| brivanib | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| dg 041 | Homo sapiens (human) | IC50 | 6.6000 | 1 | 1 |
| bms-626529 | Homo sapiens (human) | IC50 | 32.5000 | 2 | 2 |
| r 1487 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| nutlin-3a | Homo sapiens (human) | IC50 | 0.0700 | 1 | 1 |
| alogliptin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| azd 8931 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| gosogliptin | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| ce 224,535 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide | Homo sapiens (human) | IC50 | 79.4328 | 1 | 1 |
| apremilast | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| gw9508 | Homo sapiens (human) | IC50 | 33.0000 | 1 | 1 |
| cannabidivarin | Homo sapiens (human) | IC50 | 3.7000 | 1 | 1 |
| cannabidivarin | Homo sapiens (human) | Ki | 1.4000 | 1 | 1 |
| idelalisib | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| epelsiban | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| jnj 28312141 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| mk-0249 | Homo sapiens (human) | IC50 | 27.0000 | 1 | 1 |
| ku-0060648 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| dactolisib | Homo sapiens (human) | IC50 | 0.0140 | 1 | 1 |
| dihydrotetrabenazine, (2alpha,3beta,11bbeta)-isomer | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| mgl-3196 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| gsk188909 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| trelagliptin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| amodiaquine hydrochloride | Homo sapiens (human) | IC50 | 85.0000 | 2 | 2 |
| mf63 compound | Homo sapiens (human) | IC50 | 0.0019 | 1 | 1 |
| cct129202 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| vx-770 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| pamapimod | Homo sapiens (human) | IC50 | 29.0000 | 1 | 1 |
| buparlisib | Homo sapiens (human) | IC50 | 0.3720 | 1 | 1 |
| bms 687453 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| gsk 1004723 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| cct 128930 | Homo sapiens (human) | IC50 | 30.0000 | 2 | 2 |
| lu aa33810 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| azd3988 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| azd1283 | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| gsk1482160 | Homo sapiens (human) | IC50 | 0.1000 | 1 | 1 |
| serlopitant | Homo sapiens (human) | IC50 | 29.0000 | 1 | 1 |
| pf 04457845 | Homo sapiens (human) | IC50 | 0.0057 | 1 | 1 |
| gdc 0449 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| bms 754807 | Homo sapiens (human) | IC50 | 11.0000 | 1 | 1 |
| pci 32765 | Homo sapiens (human) | IC50 | 17.5256 | 3 | 3 |
| N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| at13148 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 0 |
| pf 3246799 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| cobicistat | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| pf 3845 | Homo sapiens (human) | IC50 | 0.0115 | 1 | 1 |
| glasdegib | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| azd7687 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| GDC-0623 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| osilodrostat | Homo sapiens (human) | IC50 | 0.0002 | 1 | 1 |
| e-52862 | Homo sapiens (human) | IC50 | 10.0000 | 2 | 2 |
| pki 587 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| bi 653048 bs h3po4 | Homo sapiens (human) | IC50 | 9.0000 | 1 | 1 |
| 2-((r-5-chloro-4-methoxymethylindan-1-yl)-1h-imidazole) | Homo sapiens (human) | IC50 | 5.7000 | 1 | 1 |
| bms 694153 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| n6022 | Homo sapiens (human) | IC50 | 0.7700 | 2 | 2 |
| (3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| gsk525762a | Homo sapiens (human) | IC50 | 33.0000 | 1 | 1 |
| glpg0634 | Homo sapiens (human) | IC50 | 79.1000 | 2 | 2 |
| tubastatin a | Homo sapiens (human) | IC50 | 16.4000 | 1 | 1 |
| kaf156 | Homo sapiens (human) | IC50 | 6.0000 | 2 | 2 |
| (5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| i-bet726 | Homo sapiens (human) | IC50 | 12.0000 | 1 | 1 |
| lesinurad | Homo sapiens (human) | IC50 | 27.7000 | 1 | 3 |
| 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1h-indol-5-yl)-7h-pyrrolo(2,3-d)pyrimidin-4-amine | Homo sapiens (human) | IC50 | 1.2150 | 1 | 1 |
| pf 00868554 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| dolutegravir | Homo sapiens (human) | IC50 | 67.0000 | 1 | 2 |
| ew-7197 | Homo sapiens (human) | Ki | 0.0206 | 1 | 1 |
| cep-32496 | Homo sapiens (human) | IC50 | 3.4000 | 1 | 1 |
| cep-28122 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| pbtz169 | Homo sapiens (human) | IC50 | 3.7700 | 1 | 1 |
| gsk2336805 | Homo sapiens (human) | IC50 | 33.0000 | 1 | 1 |
| cfi-400945 | Homo sapiens (human) | IC50 | 1.4000 | 1 | 1 |
| gs-9973 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| sr-3029 | Homo sapiens (human) | IC50 | 0.0440 | 1 | 1 |
| trv130 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| gne-618 | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| g007-lk | Homo sapiens (human) | IC50 | 0.0581 | 1 | 1 |
| gne-617 | Homo sapiens (human) | IC50 | 0.0020 | 1 | 1 |
| 4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide | Homo sapiens (human) | IC50 | 3.0200 | 1 | 1 |
| onc201 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| vt-1161 | Homo sapiens (human) | IC50 | 72.0000 | 1 | 1 |
| azd3759 | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| 3-chloro-5-(6-(5-fluoropyridin-2-yl)pyrimidin-4-yl)benzonitrile | Homo sapiens (human) | IC50 | 15.8489 | 1 | 1 |
| at 9283 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| 2-[(4-chlorophenyl)methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one | Homo sapiens (human) | IC50 | 6.5000 | 1 | 1 |
| bms 536924 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| ver 52296 | Homo sapiens (human) | IC50 | 0.0080 | 1 | 1 |
| 4-[[(4-oxo-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-2-yl)thio]methyl]benzoic acid methyl ester | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| XL413 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| amg 221 | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
| as1940477 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
Drugs with Activation Measurements
Drugs with Other Measurements
Design, Synthesis, and X-ray of Selenides as New Class of Agents for Prevention of Diabetic Cerebrovascular Pathology.ACS medicinal chemistry letters, , May-10, Volume: 9, Issue:5, 2018
Novel sulfonamide-containing 2-indolinones that selectively inhibit tumor-associated alpha carbonic anhydrases.Bioorganic & medicinal chemistry, , 07-15, Volume: 25, Issue:14, 2017
Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action.Journal of medicinal chemistry, , 04-13, Volume: 60, Issue:7, 2017
Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.European journal of medicinal chemistry, , Jul-23, Volume: 82, 2014
[no title available]Journal of medicinal chemistry, , 11-24, Volume: 65, Issue:22, 2022
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 24, Issue:15, 2014
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.ACS medicinal chemistry letters, , Sep-11, Volume: 5, Issue:9, 2014
[no title available],
Wake-promoting agents: search for next generation modafinil: part IV.European journal of medicinal chemistry, , Volume: 54, 2012
Wake promoting agents: search for next generation modafinil, lessons learned: part III.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 22, Issue:11, 2012
Wake-promoting agents: search for next generation modafinil: part I.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 22, Issue:6, 2012
[no title available]Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Discovery of 1-Amino-1Journal of medicinal chemistry, , 11-11, Volume: 64, Issue:21, 2021
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.Journal of medicinal chemistry, , 04-25, Volume: 62, Issue:8, 2019
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.European journal of medicinal chemistry, , Jan-01, Volume: 143, 2018
Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.Journal of medicinal chemistry, , Mar-26, Volume: 58, Issue:6, 2015
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.Journal of medicinal chemistry, , Jun-14, Volume: 55, Issue:11, 2012
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.Current drug metabolism, , Volume: 6, Issue:5, 2005
[no title available],
Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 27, Issue:16, 2017
Quinazoline derivatives as selective CYP1B1 inhibitors.European journal of medicinal chemistry, , Apr-21, Volume: 130, 2017
(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.Bioorganic & medicinal chemistry letters, , 12-15, Volume: 27, Issue:24, 2017
4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.European journal of medicinal chemistry, , Mar-05, Volume: 213, 2021
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.European journal of medicinal chemistry, , Aug-15, Volume: 200, 2020
Development of Robust 17(Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019
Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5.Journal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseaseJournal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 24, Issue:15, 2014
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.ACS medicinal chemistry letters, , Sep-11, Volume: 5, Issue:9, 2014
Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.Bioorganic & medicinal chemistry, , Jan-01, Volume: 19, Issue:1, 2011
[no title available],
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Incorporation of a chiral gem-disubstituted nitrogen heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial toxicity.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 29, Issue:18, 2019
Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.Journal of medicinal chemistry, , Nov-29, Volume: 50, Issue:24, 2007
Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.Journal of medicinal chemistry, , Dec-04, Volume: 46, Issue:25, 2003
N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 22, Issue:12, 2012
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.Journal of medicinal chemistry, , Aug-09, Volume: 50, Issue:16, 2007
Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent.Bioorganic & medicinal chemistry letters, , 09-01, Volume: 71, 2022
Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles.Bioorganic & medicinal chemistry, , 05-01, Volume: 26, Issue:8, 2018
[no title available]European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.Journal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
[no title available]Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021
N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 22, Issue:12, 2012
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.Journal of medicinal chemistry, , Aug-09, Volume: 50, Issue:16, 2007
Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 19, Issue:13, 2009
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 19, Issue:23, 2009
Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epiderJournal of medicinal chemistry, , Nov-12, Volume: 52, Issue:21, 2009
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.Journal of medicinal chemistry, , Jan-26, Volume: 55, Issue:2, 2012
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dysJournal of medicinal chemistry, , May-22, Volume: 57, Issue:10, 2014
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).Journal of medicinal chemistry, , Mar-11, Volume: 53, Issue:5, 2010
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.Journal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008
Discovery and Evaluation of Pyrazolo[3,4-ACS medicinal chemistry letters, , Oct-08, Volume: 11, Issue:10, 2020
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.Journal of medicinal chemistry, , 09-12, Volume: 62, Issue:17, 2019
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.Bioorganic & medicinal chemistry letters, , 11-15, Volume: 28, Issue:21, 2018
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 28, Issue:17, 2018
Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.ACS medicinal chemistry letters, , May-12, Volume: 2, Issue:5, 2011
Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 21, Issue:19, 2011
Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.Journal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in cJournal of medicinal chemistry, , Dec-13, Volume: 55, Issue:23, 2012
Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/Journal of medicinal chemistry, , May-22, Volume: 57, Issue:10, 2014
Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Enables
This protein enables 14 target(s):
| Target | Category | Definition |
|---|
| monooxygenase activity | molecular function | Catalysis of the incorporation of one atom from molecular oxygen into a compound and the reduction of the other atom of oxygen to water. [ISBN:0198506732] |
| iron ion binding | molecular function | Binding to an iron (Fe) ion. [GOC:ai] |
| steroid hydroxylase activity | molecular function | Catalysis of the formation of a hydroxyl group on a steroid by incorporation of oxygen from O2. [ISBN:0721662544] |
| oxidoreductase activity | molecular function | Catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced. [GOC:go_curators] |
| (S)-limonene 6-monooxygenase activity | molecular function | Catalysis of the reaction: (-)-limonene + NADPH + H+ + O2 = (-)-trans-carveol + NADP+ + H2O. [EC:1.14.14.51] |
| (S)-limonene 7-monooxygenase activity | molecular function | Catalysis of the reaction: (4S)-limonene + H+ + NADPH + O2 = (4S)-perillyl alcohol + H2O + NADP+. [EC:1.14.14.52, RHEA:23432] |
| oxygen binding | molecular function | Binding to oxygen (O2). [GOC:jl] |
| enzyme binding | molecular function | Binding to an enzyme, a protein with catalytic activity. [GOC:jl] |
| heme binding | molecular function | Binding to a heme, a compound composed of iron complexed in a porphyrin (tetrapyrrole) ring. [GOC:ai] |
| (R)-limonene 6-monooxygenase activity | molecular function | Catalysis of the reaction: (4R)-limonene + H+ + NADPH + O2 = (1R,5S)-carveol + H2O + NADP+. [EC:1.14.14.53, RHEA:18957] |
| aromatase activity | molecular function | Catalysis of the reduction of an aliphatic ring to yield an aromatic ring. [GOC:cb] |
| long-chain fatty acid omega-1 hydroxylase activity | molecular function | Catalysis of the reaction: an (omega-1)-ethyl long-chain fatty acid + O2 + reduced [NADPH-hemoprotein reductase] = an (omega-1)-hydroxy-long-chain fatty acid + H+ + H2O + oxidized [NADPH-hemoprotein reductase. [GOC:nhn, PMID:18577768, PMID:22772592, PMID:24242247, RHEA:60936] |
| arachidonic acid epoxygenase activity | molecular function | Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to a cis-epoxyeicosatrienoic acid. [http://lipidlibrary.aocs.org/Lipids/eic_hete/index.htm, PMID:10681399, PMID:18952572] |
| oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | molecular function | Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from reduced flavin or flavoprotein and one other donor, and one atom of oxygen is incorporated into one donor. [GOC:mah] |
Located In
This protein is located in 3 target(s):
| Target | Category | Definition |
|---|
| endoplasmic reticulum membrane | cellular component | The lipid bilayer surrounding the endoplasmic reticulum. [GOC:mah] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| intracellular membrane-bounded organelle | cellular component | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. [GOC:go_curators] |
Active In
This protein is active in 2 target(s):
| Target | Category | Definition |
|---|
| intracellular membrane-bounded organelle | cellular component | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. [GOC:go_curators] |
| cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
Involved In
This protein is involved in 7 target(s):
| Target | Category | Definition |
|---|
| long-chain fatty acid metabolic process | biological process | The chemical reactions and pathways involving a long-chain fatty acid. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons. [GOC:ajp] |
| xenobiotic metabolic process | biological process | The chemical reactions and pathways involving a xenobiotic compound, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:cab2, GOC:krc] |
| steroid metabolic process | biological process | The chemical reactions and pathways involving steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus. [ISBN:0198547684] |
| monoterpenoid metabolic process | biological process | The chemical reactions and pathways involving monoterpenoid compounds, terpenoids having a C10 skeleton. [ISBN:0198547684] |
| epoxygenase P450 pathway | biological process | The chemical reactions and pathways by which arachidonic acid is converted to other compounds including epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids. [GOC:mah, PMID:17979511] |
| xenobiotic catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of a xenobiotic compound, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| omega-hydroxylase P450 pathway | biological process | The chemical reactions and pathways by which arachidonic acid is converted to other compounds initially by omega-hydroxylation. [GOC:mw, PMID:10681399] |